Journal for ImmunoTherapy of Cancer · 2023 · 12 citations · 36 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyImmunotherapy For Solid TumorsOvarian CancerTumor AntigensAberrant Glycosylation In CancerAberrant O-glycosylation In CancerCancer AntigensImmunotherapy For Ovarian CancerOvarian Cancer ImmunologySolid Tumor Car T-cell TherapyTumor Antigen-based ImmunotherapyTumor Progression Dynamics
Background Treatment of some blood cancers with T cells that express a chimeric antigen receptor (CAR) against CD19 have shown remarkable results. In contrast, CAR-T cell efficacy against solid tumors has been difficult to achieve. Methods To examine the potential of CAR-T cell treatments against ovarian cancers, we used the mouse ovarian cancer cell line ID8 in an intraperitoneal model that exhibits disseminated solid tumors in female C57BL/6J mice. The CAR contained a single-chain Fv from antibody 237 which recognizes a Tn-glycopeptide-antigen expressed by ID8 due to aberrant O-linked glycosylation in the absence of the transferase-dependent chaperone Cosmc . The efficacy of four Tn-dependent CARs with varying affinity to Tn antigen, and each containing CD28/CD3ζ cytoplasmic domains, were compared in vitro and in vivo in this study. Results In line with many observations about the impact of aberrant O-linked glycosylation, the ID8 Cosmc knock-out (ID8 Cosmc -KO) exhibited more rapid tumor progression compared with wild-type ID8. Despite the enhanced tumor growth in vivo, 237 CAR and a mutant with 30-fold higher affinity, but not CARs with lower affinity, controlled advanced ID8 Cosmc -KO tumors. Tumor regression could be achieved with a single intravenous dose of the CARs, but intraperitoneal administration was even more effective. The CAR-T cells persisted over a period of months, allowing CAR-treated mice to delay tumor growth in a re-challenge setting. The most effective CARs exhibited the highest affinity for antigen. Antitumor effects observed in vivo were associated with increased numbers of T cells and macrophages, and higher levels of cleaved caspase-3, in the tumor microenvironment. Notably, the least therapeutically effective CAR mediated tonic signaling leading to antigen-independent cytokine expression and it had higher levels of the immunosuppressive cytokine interleukin10. Conclusion The findings support the development of affinity-optimized CAR-T cells as a potential treatment for established ovarian cancer, with the most effective CARs mediating a distinct pattern of inflammatory cytokine release in vitro. Importantly, the most potent Tn-dependent CAR-T cells showed no evidence of toxicity in tumor-bearing mice in a syngeneic, immunocompetent system.
36
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai, Kanyawim Kirtikara · Nature Protocols · 2006 · 3.7K citations
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
J. Joseph Melenhorst, Gregory M. Chen, Meng Wang et al. · Nature · 2022 · 920 citations · Full text
Development of a syngeneic mouse model for events related to ovarian cancer
Katherine F. Roby, Christopher Taylor, J. P. Sweetwood et al. · Carcinogenesis · 2000 · 597 citations · Full text